Nicola Virtuoso
Overview
Explore the profile of Nicola Virtuoso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Izzo C, Visco V, Cirillo A, Bonadies D, Caliendo G, Rusciano M, et al.
J Cardiovasc Dev Dis
. 2024 Dec;
11(12).
PMID: 39728279
Severe obesity is closely associated with an increased risk of comorbidities and alterations in cardiac structure and function. The primary objective of this study was to investigate cardiovascular (CV) risk...
2.
Loria F, Mone P, Rispoli A, Di Fonzo R, Masarone D, Mancusi C, et al.
Cardiovasc Diabetol
. 2024 Nov;
23(1):423.
PMID: 39578847
Background: Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) represent a deep revolution of the therapeutic approach to heart failure (HF), preventing its insurgence but also improving the management of the disease and slowing...
3.
Santulli G, Visco V, Ciccarelli M, Ferrante M, De Masi P, Pansini A, et al.
Cardiovasc Diabetol
. 2024 May;
23(1):180.
PMID: 38811990
No abstract available.
4.
Secondulfo C, Visco V, Virtuoso N, Fortunato M, Migliarino S, Rispoli A, et al.
Life (Basel)
. 2024 May;
14(5).
PMID: 38792638
Chronic kidney disease (CKD) and cardiovascular disease (CVD) are highly prevalent conditions, each significantly contributing to the global burden of morbidity and mortality. CVD and CKD share a great number...
5.
Visco V, Esposito C, Rispoli A, Di Pietro P, Izzo C, Loria F, et al.
ESC Heart Fail
. 2024 May;
11(5):2835-2848.
PMID: 38761030
Aims: We report the results of a real-world study based on heart failure (HF) patients' continuous remote monitoring strategy using the CardioMEMS system to assess the impact of this device...
6.
Santulli G, Visco V, Ciccarelli M, Ferrante M, De Masi P, Pansini A, et al.
Cardiovasc Diabetol
. 2024 Apr;
23(1):125.
PMID: 38600564
Background: Hypertension and chronic kidney disease (CKD) pose significant public health challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized as a precursor to diabetes and is often accompanied by cardiovascular...
7.
Izzo C, Secondulfo C, Bilancio G, Visco V, Virtuoso N, Migliarino S, et al.
Life (Basel)
. 2024 Mar;
14(3).
PMID: 38541742
Chronic kidney disease (CKD) is a global health issue with a rising prevalence, affecting 697.5 million people worldwide. It imposes a substantial burden, contributing to 35.8 million disability-adjusted life years...
8.
Visco V, Izzo C, Bonadies D, Di Feo F, Caliendo G, Loria F, et al.
J Cardiovasc Dev Dis
. 2023 Aug;
10(8).
PMID: 37623340
Obesity is a growing public health epidemic worldwide and is implicated in slowing improved life expectancy and increasing cardiovascular (CV) risk; indeed, several obesity-related mechanisms drive structural, functional, humoral, and...
9.
Campanile A, Visco V, De Carlo S, Ferruzzi G, Mancusi C, Izzo C, et al.
Life (Basel)
. 2023 May;
13(5).
PMID: 37240819
Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity remain uncertain; consequently, we sought to compare...
10.
Visco V, Izzo C, Mancusi C, Rispoli A, Tedeschi M, Virtuoso N, et al.
J Cardiovasc Dev Dis
. 2023 Feb;
10(2).
PMID: 36826570
Arterial hypertension (AH) is a progressive issue that grows in importance with the increased average age of the world population. The potential role of artificial intelligence (AI) in its prevention...